<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01324089</url>
  </required_header>
  <id_info>
    <org_study_id>CO 10308</org_study_id>
    <secondary_id>R21CA149560</secondary_id>
    <secondary_id>A534260</secondary_id>
    <secondary_id>SMPH\MEDICINE\HEM-ONC</secondary_id>
    <secondary_id>NCI-2012-00072</secondary_id>
    <secondary_id>2010-0356</secondary_id>
    <nct_id>NCT01324089</nct_id>
  </id_info>
  <brief_title>Resveratrol With or Without Piperine to Enhance Plasma Levels of Resveratrol</brief_title>
  <official_title>A Randomized, Double-Blind Pilot Trial of Resveratrol With or Without Piperine to Enhance Plasma Levels of Resveratrol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is some evidence that when resveratrol (a substance which is found in red grapes,&#xD;
      peanuts and chocolate) is combined with Piperine (a substance found in pepper) it is more&#xD;
      effective in fighting cancer. The purpose of this study is to see if resveratrol in&#xD;
      combination with piperine is more effective than taking resveratrol alone. Since&#xD;
      investigators don't know what dose of piperine to use in combination with resveratrol, two&#xD;
      different doses of piperine will be studied.&#xD;
&#xD;
      Twenty-four participants, equal numbers of males and females, will receive a single dose of&#xD;
      resveratrol (2.5 grams) without piperine, resveratrol (2.5 grams) with piperine (5 mg), or&#xD;
      resveratrol (2.5 grams) with piperine (25 mg).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood levels of study drugs</measure>
    <time_frame>30 days</time_frame>
    <description>Blood levels of Resveratrol/Piperine will be measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects of study drugs</measure>
    <time_frame>30 days</time_frame>
    <description>Adverse events or side effects</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Focus of the Study: Normal Volunteers</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Resveratrol 2.5 grams x 1 dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Resveratrol</intervention_name>
    <description>Resveratrol 2.5 grams</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose</intervention_name>
    <description>Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose</intervention_name>
    <description>Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women age 18 to 65 years old, inclusive&#xD;
&#xD;
          -  Women and men must agree to use an effective form of birth control prior to study&#xD;
             entry and for the duration of study participation&#xD;
&#xD;
          -  Willingness to abstain from foods containing resveratrol for 3 days prior to single&#xD;
             dose administration and for 7 days after dosing. (Examples include red grapes, grape&#xD;
             juice, peanuts, peanut butter.)&#xD;
&#xD;
          -  Abstain from vitamin supplements from 2 weeks before study dosing and for 7 days&#xD;
             following study dosing&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status â‰¤ 1 (Karnofsky &gt; 70%)&#xD;
&#xD;
          -  Participants must have normal organ and hepatic functions&#xD;
&#xD;
          -  Participants must abstain from alcohol beverages 72 hours prior to dosing with the&#xD;
             study agent, and for 7 days after dosing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who require daily medication, either prescription or over the counter&#xD;
             (with the exception of birth control pills) will be considered ineligible.&#xD;
             Participants who occasionally use medication (such as for pain relief or allergies)&#xD;
             will be considered eligible; however, these participants must agree to refrain from&#xD;
             using prn medications starting at midnight prior to the inpatient period and for seven&#xD;
             days following dosing.&#xD;
&#xD;
          -  Any cancer diagnosis within the past 5 years (except basal cell carcinoma or squamous&#xD;
             cell carcinoma).&#xD;
&#xD;
          -  Participants may not be currently receiving any other investigational agent(s) or have&#xD;
             taken any within the past 9 months.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition of resveratrol and/or piperine.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard H Bailey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>March 8, 2011</study_first_submitted>
  <study_first_submitted_qc>March 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2011</study_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Resveratrol</keyword>
  <keyword>Piperine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
    <mesh_term>Piperine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

